News and Press Releases

1nhaler hires pharma industry leaders for key roles ahead of clinical trials

Edinburgh-based 1nhaler has appointed two experts in inhalation and respiratory medicines to the board as it looks to accelerate the development and market-readiness of its novel single use inhaler device....

Category: Clinical Trials, Other
Posted: July 1, 2024

1 (2F3) Jessfield Terrace, Edinburgh, Scotland, EH6 4JR

New study investigates link between toxic element exposure and Alzheimer’s disease risk

25 June 2024 -- Malvern, UK -- A comprehensive study is currently underway to clarify the relationship between Alzheimer's disease and related dementias (AD/ADRD) and four toxic elements: lead, mercury, arsenic...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 27, 2024

Enigma Business Park Grovewood Road Malvern WR14 1XZ United Kingdom

Bio-Rad Extends Range of Anti-Biotherapeutic Antibodies to Accelerate Antibody Drug Development

Four New Anti-Idiotypic Antibodies and a New Anti-MMAE Antibody Range Support Bioanalytical Assay Development for Preclinical Research and Clinical Trials June 24 2024, California, US, -Bio-Rad Laboratories, Inc. (NYSE: BIO...

Category: BioManufacturing, Clinical Trials, Drug Discovery
Posted: June 24, 2024

Bio-Rad Laboratories Ltd. The Junction Station Road Watford Hertfordshire WD17 1ET

Patients Most In Need Face Obstacles to Participating in Life-Saving Clinical Trials According to a New Milken Institute Report

24 June 2024 -- Washington, DC -- Clinical trials can provide the possibility to obtain novel treatments for conditions and diseases that are not yet commercially available. Yet, these lifesaving...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 24, 2024

730 15th Street NW Washington, DC 20005

New Phesi proof of concept demonstrates potential of AI-powered digital twins to replace external control arms in clinical trials

Study published in Bone Marrow Transplantation uses real-world clinical data to create virtual digital twin cohorts instead of placebo and standard-of-care comparator arms 20 June 2024 -- Massachusetts, US --...

Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: June 20, 2024

East Lyme, Connecticut, US

China’s Innovent holds potential to change pancreatic cancer treatment landscape with bispecific antibody IBI389, says GlobalData

14 June 2024 - China-based Innovent Biologics recently presented phase 1 study results of its first-in-class anti-CLDN18.2/CD3 bispecific antibody (IBI389) for the treatment of advanced pancreatic cancer at the 2024...

Category: Biotechnology, Pharmaceutical
Posted: June 14, 2024

GlobalData, John Carpenter House, 7 Carmelite Street, London, EC4Y 0BS, United Kingdom

Tapinarof may mark Dermavant’s first atopic dermatitis approval, says GlobalData

Dermavant's VTAMA (tapinarof), a nonsteroidal, topical AhR-modulating agent, achieved positive phase 3 trial results in atopic dermatitis patients aged two and above, leading to Food and Drug Administration (FDA) acceptance...

Category: Drug Discovery, Pharmaceutical
Posted: June 13, 2024

GlobalData, John Carpenter House, 7 Carmelite Street, London, EC4Y 0BS, United Kingdom

IQVIA Launches “One Home” Clinical Trial Technology Platform – Solves Challenges and Reduces Overload at Sites

Bold initiative to boost the capacity of research sites enters Beta testing and piloting 12 June 2024 -- North Carolina, US -- IQVIA today announced the launch of One Home...

Category: Clinical Trials, Drug Discovery, Other
Posted: June 12, 2024

CluePoints, a leading provider of AI-driven software solutions for Clinical Data Review, receives significant investment for continued growth from EQT

CluePoints is a cloud-based software platform for Risk-Based Quality Management (RBQM) and data quality oversight in clinical trials, designed to enable safer and more efficient processes and improving data integrity...

Category: Biotechnology, Clinical Trials
Posted: June 12, 2024

1000 Continental Drive, Suite 240, King of Prussia, PA 19406

SciRhom Announces Approval of First Clinical Trial Application for a Novel iRhom2-targeting Antibody Against Autoimmune Diseases

12 June 2024 -- Munich, Germany -- SciRhom GmbH, a biopharmaceutical company pioneering the development of first-in-class therapeutic antibodies, announced today the approval of a clinical trial application (CTA) by...

Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: June 12, 2024

Am Klopferspitz 19 82152 Planegg/Martinsried Germany

Asgard Therapeutics selects Exothera to bring their viral vector-based immunotherapy candidate AT-108 to clinical trial stage

11 June 2024 -- Lund, Sweden -- Asgard Therapeutics, a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy, today announced it selected Exothera, a leading...

Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: June 11, 2024

Medicon Village, 223 81 Lund, Sweden

CRISM Therapeutics Corp to continue pioneering R&D at PHTA following listing on the London Stock Exchange

11 June 2024 -- Birmingham, UK -- CRISM Therapeutics Corporation a UK-based pharmaceutical company focused on improving the clinical performance of cancer treatments for solid tumours, has raised £2.0m to...

Category: Biotechnology, Clinical Trials, Drug Delivery, Pharmaceutical
Posted: June 11, 2024

Kingston Chambers, PO Box 173, Road Town Tortola, British Virgin Islands

Kite’s TECARTUS (Brexucabtagene Autoelucel) Demonstrates Sustained Overall Survival in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia

After more than four years of follow-up in the pivotal ZUMA-3 study, median overall survival was 26 months and four-year overall survival rate was 40% at 48 months Survival benefit...

Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: June 3, 2024

2400 Broadway Santa Monica, CA 90404

TECVAYLI▼ (teclistamab) shows sustained deep and durable responses in patients with relapsed or refractory multiple myeloma

New MajesTEC-1 data show a median duration of response of 24 months, with responses deepening, including in patients who switched to biweekly dosing Separate analyses from the MajesTEC-1 and OPTec...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 3, 2024

Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

First participant dosed in research study investigating the effects of BPL-003, a novel formulation of 5-MeO-DMT, on the human brain

The study is the first of its kind to assess the effects of 5-MeO-DMT in the human brain and will investigate the neurophysiological effects of BPL-003, Beckley Psytech’s novel synthetic...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 3, 2024

Beckley Park Beckley OXFORD, OX3 9SY United Kingdom